Cancer therapy ovarian carcinoma

Covens A, Boucher S, Roche K, et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma Cancer 1996 77 2086-2091. 

In patients with epithelial ovarian carcinomas, serum Mn-SOD levels increased in accordance with the clinical progression of disease. At the early stage, however, the incidence of cases with elevated serum levels was low. Therefore measurements of serum Mn-SOD may not always be useful for the early diagnosis of epithelial ovarian carcinoma. The decline in serum Mn-SOD levels following affective therapy seems to reflect the disappearance of lesions. Decreases occurred after therapy and increases occurred with recurrences. Thus it appears that the measurement of this enzyme in serum can provide useful data for monitoring epithelial ovarian cancer following therapy, and for the early diagnosis of recurrences of the disease. 

Metal-based drugs have probably had most impact in the area of cancer therapy, with cisplatin still used to treat approximately 70% of all cancer patients. Cisplatin is particularly useful for treatment of testicular, ovarian, oropharyngeal, bronchogenic, cervical, and bladder carcinomas, lymphoma, osteosarcoma, melanoma, and neuroblastoma. Metallocene-type compounds were the first organometallic compounds to be evaluated in cancer therapy, and until recently, Ti(77 -C5H5)2Cl2 was undergoing clinical trials (see above). Despite this setback to the field,... 

Peterson CM, Lu JM, Sun Y, Peterson CA, Shiah JG, Straight RC, Kopecek J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res 1996 56 3980-3985. 

An NIH panel on ovarian cancer advised that innovative approaches to the treatment of advanced primary as well as recurrent ovarian cancer must be identified and studied . [2] Williams reached similar conclusions, namely that there are two striking needs in the therapy of ovarian carcinoma new more effective dmgs and development of best current therapy using dmgs presently available . [9]... 

Son, K.K. and Hall, K.J. (2000). Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther. 7,1324—1328. 

Paclitaxel is among the most active of all anticancer drugs, with significant efficacy against carcinomas of the breast, ovary, lung, head, and neck. It is combined with cisplatin in the therapy of ovarian and lung carcinomas and with doxorubicin in treating breast cancer. 

Therapeutic applications Fluorouracil is employed primarily in the treatment of slowly growing, solid tumors (for example, colorectal, breast, ovarian, pancreatic, and gastric carcinomas). Adjuvant therapy with levamisole, a veterinary anthelmintic agent, improves the survival of patients with colonic cancer. 5-FU is also effective for the treatment of superficial basal cell carcinom when applied topically. 

Tanioxircn hits seen extensive use in treating primary breast cancers that arc ER dependent, For premenopausal women with metastatic disease, tamoxifen is an alternative and adjuvant with oophorectomy, ovarian irradiation, and mastectomy. Tamoxifen u.se. however, is not problem free. Tamoxifen increases the incidence of endometrial polyps. hyperplasia, and carcinoma and uterine sarcomas. The risk of endometrial cancer resulting from tamoxifen is. however. much lower than the "modest but highly significant reductions in morbidity and mortality of breast cancer." Becau.se of the increased risk of endometrial cancer with tamoxifen therapy, tamoxifen. should be u.sed to prevent breast cancer only in women at high ri.sk. Women without a family history of breast cancer or other risks should not use tamoxifen in this manner. 

---